See more : Maschinenfabrik Heid AG (HED.VI) Income Statement Analysis – Financial Results
Complete financial analysis of Acacia Pharma Group plc (ACPH.BR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acacia Pharma Group plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Toho Co., Ltd. (TKCOF) Income Statement Analysis – Financial Results
- AQ Group AB (publ) (AQ.ST) Income Statement Analysis – Financial Results
- Keller Group plc (KLR.L) Income Statement Analysis – Financial Results
- SUZHOU KEMATEK INC (301611.SZ) Income Statement Analysis – Financial Results
- The Berkeley Group Holdings plc (BKG.L) Income Statement Analysis – Financial Results
Acacia Pharma Group plc (ACPH.BR)
About Acacia Pharma Group plc
Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.16M | 211.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 295.00K | 29.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 868.00K | 182.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 74.63% | 86.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.07M | 99.00K | 3.93M | 4.78M | 2.00M | 16.79M | 14.93M |
| General & Administrative | 18.03M | 11.57M | 4.45M | 5.49M | 2.07M | 1.03M | 3.54M |
| Selling & Marketing | 32.00M | 19.44M | 14.02M | 8.81M | 0.00 | 0.00 | 0.00 |
| SG&A | 50.03M | 31.00M | 18.47M | 14.30M | 2.07M | 1.03M | 3.54M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 54.10M | 31.10M | 22.39M | 19.08M | 4.07M | 17.82M | 18.47M |
| Cost & Expenses | 54.39M | 31.13M | 22.39M | 19.08M | 4.07M | 17.82M | 18.47M |
| Interest Income | 2.00K | 41.00K | 432.00K | 310.88K | 2.70K | 8.64K | 28.15K |
| Interest Expense | 3.34M | 2.19M | 1.49M | 2.36M | 2.03M | 667.49K | 0.00 |
| Depreciation & Amortization | 8.19M | 3.15M | 95.00K | 909.81K | -2.71M | -1.61M | -3.89M |
| EBITDA | -56.49M | -28.76M | -21.92M | -18.17M | -6.78M | -19.43M | -22.36M |
| EBITDA Ratio | -4,857.01% | -13,628.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -64.68M | -30.92M | -22.39M | -19.08M | -4.07M | -17.82M | -18.47M |
| Operating Income Ratio | -5,561.13% | -14,654.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.34M | -3.17M | -1.11M | -1.45M | -4.74M | -2.28M | -3.89M |
| Income Before Tax | -68.01M | -34.09M | -23.51M | -20.53M | -8.81M | -20.10M | -22.36M |
| Income Before Tax Ratio | -5,848.15% | -16,157.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -940.00K | -614.00K | -668.00K | -837.48K | -471.64K | -3.45M | -3.29M |
| Net Income | -67.07M | -33.48M | -22.84M | -19.69M | -8.34M | -16.65M | -19.07M |
| Net Income Ratio | -5,767.33% | -15,866.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -0.62 | -0.43 | -0.45 | -0.16 | -6.27 | -7.18 |
| EPS Diluted | -0.84 | -0.62 | -0.43 | -0.45 | -0.16 | -6.27 | -7.18 |
| Weighted Avg Shares Out | 79.87M | 53.68M | 53.68M | 44.09M | 52.92M | 2.66M | 2.66M |
| Weighted Avg Shares Out (Dil) | 79.87M | 53.68M | 53.68M | 44.09M | 52.92M | 2.66M | 2.66M |
Source: https://incomestatements.info
Category: Stock Reports